Lakewood-Amedex Biotherapeutics Inc. stock analysis
Lakewood-Amedex Biotherapeutics Inc. (LABT) Stock Price & Analysis
LABT Stock Chart & Stats
- Day’s Range
- $0.35 - $0.39
- 52-Week Range
- $0.17 - $98.20
- Previous Close
- $0.40
- Volume
- N/A
- Average Volume (3M)
- 29.01M
- Market Cap
- $936.03K
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- $4.58M
- Total Debt (Recent Filing)
- $101.62K
- Price to Earnings (P/E)
- ―
- Beta
- -5.35
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Lakewood-Amedex Biotherapeutics Inc. News
Lakewood-Amedex Biotherapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Lakewood-Amedex Biotherapeutics (LABT) with a Buy rating and $3 price target Lakewood-Amedex is a clinical-stage biotech developing Bisphosphocins, a novel class of locally delivered antibiotics
Lakewood-Amedex announces preclinical data from Bisphosphocin studies
Lakewood-Amedex Biotherapeutics (LABT) announced positive preclinical data in urinary tract infection, or UTI, and pulmonary infection indications in animal models treated with Bisphosphocin compounds. In an animal model of UTI,
Lakewood-Amedex Biotherapeutics reports positive MIC data from Nu-3 study
Lakewood-Amedex Biotherapeutics (LABT) announced positive Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical candidate, Nu-3. Nu-3 is currently being investigated in a Phase 2a clinical trial
Lakewood-Amedex announces preclinical data from Phase 2a clinical trial
Lakewood-Amedex Biotherapeutics (LABT) announced robust preclinical safety data that establishes a strong foundation for clinical dose selection in its upcoming Phase 2a clinical trial. “These preclinical results are highly encouraging,
Lakewood-Amedex supports reintroduction of PASTEUR act
Lakewood-Amedex Biotherapeutics (LABT) announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance, PASTEUR, Act, legislation designed to “encourage” the development of novel therapies
LABT FAQ
What was Lakewood-Amedex Biotherapeutics Inc.’s price range in the past 12 months?
What is Lakewood-Amedex Biotherapeutics Inc.’s market cap?
When is Lakewood-Amedex Biotherapeutics Inc.’s upcoming earnings report date?
Is Lakewood-Amedex Biotherapeutics Inc. overvalued?
Does Lakewood-Amedex Biotherapeutics Inc. pay dividends?
What is Lakewood-Amedex Biotherapeutics Inc.’s EPS estimate?
How many shares outstanding does Lakewood-Amedex Biotherapeutics Inc. have?
Which hedge fund is a major shareholder of Lakewood-Amedex Biotherapeutics Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Kelvin Cooper
- Employees
- 5
- Website
- www.lakewoodamedex.com
- Address
- 8031 Cooper Creek Blvd., Unit 103, University Park, FL, 34201, US
LABT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 6 | 11 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 1 | 0 | 9 |
